{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:57:13Z","timestamp":1794333433529,"version":"4.9.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/01223"],"award-info":[{"award-number":["PI22\/01223"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI22\/00321"],"award-info":[{"award-number":["FI22\/00321"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01500"],"award-info":[{"award-number":["PI21\/01500"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-66097-w","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T23:02:26Z","timestamp":1766530946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6315-7919","authenticated-orcid":false,"given":"Mariano","family":"Provencio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8927-9129","authenticated-orcid":false,"given":"Bego\u00f1a","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Guirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Garc\u00eda Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Dorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"V\u00e1zquez Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asia","family":"Ferr\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. \u00c1ngeles","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-3371","authenticated-orcid":false,"given":"Ana Laura","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Insa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carmen","family":"Areses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-3436","authenticated-orcid":false,"given":"Ivana","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delvys","family":"Rodriguez-Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bosch-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"L\u00f3pez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Mars\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Torrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Matskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Giner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Fern\u00e1ndez Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"S\u00e1nchez Saugar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mart\u00ednez-Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Mediavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1634-7397","authenticated-orcid":false,"given":"Atocha","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-7011","authenticated-orcid":false,"given":"Alberto","family":"Cruz-Berm\u00fadez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"66097_CR1","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","volume":"28","author":"A Aup\u00e9rin","year":"2010","unstructured":"Aup\u00e9rin, A. et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non - small-cell lung cancer. J. Clin. Oncol. 28, 2181\u20132190 (2010).","journal-title":"J. Clin. Oncol."},{"key":"66097_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1056\/NEJM199202203260805","volume":"326","author":"C Schaake-Koning","year":"1992","unstructured":"Schaake-Koning, C. et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 326, 524\u201330 (1992).","journal-title":"N. Engl. J. Med."},{"key":"66097_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1200\/JCO.1995.13.2.452","volume":"13","author":"B Jeremic","year":"1995","unstructured":"Jeremic, B., Shibamoto, Y., Acimovic, L. & Djuric, L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J. Clin. Oncol. 13, 452\u2013458 (1995).","journal-title":"J. Clin. Oncol."},{"key":"66097_CR4","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. N. Engl. J. Med. 377, 1919\u20131929 (2017).","journal-title":"N. Engl. J. Med."},{"key":"66097_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q. et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 23, 209\u2013219 (2022).","journal-title":"Lancet Oncol."},{"key":"66097_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.lungcan.2022.10.006","volume":"174","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer 174, 112\u2013117 (2022).","journal-title":"Lung Cancer"},{"key":"66097_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jtho.2020.10.129","volume":"16","author":"S Peters","year":"2021","unstructured":"Peters, S. et al. Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platf. J. Thorac. Oncol. 16, 278\u2013288 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"66097_CR8","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1001\/jamaoncol.2021.2301","volume":"7","author":"SK Jabbour","year":"2021","unstructured":"Jabbour, S. K. et al. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol. 7, 1351\u20131359 (2021).","journal-title":"JAMA Oncol."},{"key":"66097_CR9","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1016\/j.cllc.2021.07.005","volume":"23","author":"D De Ruysscher","year":"2022","unstructured":"De Ruysscher, D. et al. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. Clin. Lung Cancer 23, e264\u2013e268 (2022).","journal-title":"Clin. Lung Cancer"},{"key":"66097_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102986","volume":"9","author":"JD Bradley","year":"2024","unstructured":"Bradley, J. D. et al. LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2. ESMO Open 9, 102986 (2024).","journal-title":"ESMO Open"},{"key":"66097_CR11","doi-asserted-by":"publisher","unstructured":"Provencio, M., Calvo, V., Romero, A., Spicer, J. D. & Cruz-Berm\u00fadez, A. Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy. Am. Soc. Clin. Oncol. Educ. B. 1\u201318 https:\/\/doi.org\/10.1200\/EDBK_358995 (2022).","DOI":"10.1200\/EDBK_358995"},{"key":"66097_CR12","first-page":"1","volume":"60607","author":"HJ Ross","year":"2024","unstructured":"Ross, H. J. et al. Atezolizumab before and after Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial. JAMA Oncol. 60607, 1\u20138 (2024).","journal-title":"JAMA Oncol."},{"key":"66097_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","volume":"21","author":"M Provencio","year":"2020","unstructured":"Provencio, M. et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 21, 1413\u20131422 (2020).","journal-title":"Lancet Oncol."},{"key":"66097_CR14","doi-asserted-by":"publisher","unstructured":"Provencio, M. et al. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). J. Clin. Oncol. JCO2102660 https:\/\/doi.org\/10.1200\/JCO.21.02660 (2022).","DOI":"10.1200\/JCO.21.02660"},{"key":"66097_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio, M. et al. Perioperative Nivolumab and Chemotherapy in Stage III Non\u2013Small-Cell Lung Cancer. N. Engl. J. Med. 389, 504\u2013513 (2023).","journal-title":"N. Engl. J. Med."},{"key":"66097_CR16","doi-asserted-by":"publisher","unstructured":"Provencio, M. et al. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. Lancet Oncol. 1453\u20131464 https:\/\/doi.org\/10.1016\/S1470-2045(24)00498-4 (2024).","DOI":"10.1016\/S1470-2045(24)00498-4"},{"key":"66097_CR17","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N. Engl. J. Med. 386, 1973\u20131985 (2022).","journal-title":"N. Engl. J. Med."},{"key":"66097_CR18","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone, T. et al. Perioperative Nivolumab in Resectable Lung Cancer. N. Engl. J. Med. 390, 1756\u20131769 (2024).","journal-title":"N. Engl. J. Med."},{"key":"66097_CR19","doi-asserted-by":"publisher","unstructured":"Deutsch, J. S. et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-023-02660-6 (2023).","DOI":"10.1038\/s41591-023-02660-6"},{"key":"66097_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","volume":"18","author":"N Girard","year":"2023","unstructured":"Girard, N. et al. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J. Thorac. Oncol. 18, 181\u2013193 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"66097_CR21","doi-asserted-by":"publisher","first-page":"E2249591","DOI":"10.1001\/jamanetworkopen.2022.49591","volume":"6","author":"ES Lebow","year":"2023","unstructured":"Lebow, E. S. et al. Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiation and Durvalumab. JAMA Netw. Open 6, E2249591 (2023).","journal-title":"JAMA Netw. Open"},{"key":"66097_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijrobp.2022.02.014","volume":"113","author":"N Shaverdian","year":"2022","unstructured":"Shaverdian, N. et al. Effects of Tumor Mutational Burden and Gene Alterations Associated with Radiation Response on Outcomes of Postoperative Radiation Therapy in Non-Small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys. 113, 335\u2013344 (2022).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66097-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66097-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66097-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T23:02:27Z","timestamp":1766530947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66097-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66097"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66097-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.P. reports grants, consulting fees and non-financial support from BMS; grants, consulting fees and non-financial support from Roche; grants, consulting fees and non-financial support from Astra Zeneca; consulting fees from MSD; consulting fees from Takeda; outside the submitted work. B.C. reports payment or honoraria from BMS, Astra Zeneca, Novartis, Amgen; support for attending meetings or travels from Roche, Astra Zeneca, GSK, Lilly; and advisory board from Roche and Astra Zeneca. R.G.-C. reports payment or honoraria from AstraZeneca, BMS, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, and Takeda; support for attending meetings or travel from AstraZeneca, Roche, Pfizer, BMS, MSD, and Janssen; and advisory board participation with AstraZeneca and Janssen. M.D. reports payment or honoraria from Janssen, Bristol Myers Squibb, AstraZeneca, MSD, Guardant; support for attending meetings or travels from Janssen; advisory Board participation with Bristol Myers Squibb. S.V-E. reports consulting fees from AstraZeneca; payment or honoraria from AstraZeneca; support for attending meetings or travels from AstraZeneca. A.F. reports payment or honoraria from AstraZeneca; support for attending meetings or travels from Merck, MSD, Pfizer. A.B. reports consulting fees from AZ; payment Honoraria from Regeneron; support for attending meetings or travels from Roche Pharma. A.I. reports payment or honoraria from Amgen, BMS, Regeneron, Roche, Takeda; support for attending meetings or travel: Roche, Pfizer, MSD, Takeda; and advisory board participation with AstraZeneca, Roche, Pfizer, Takeda. M.C-A. reports payment or honoraria: Roche, Bristol, MSD, AstraZeneca, Janssen, Pfizer, Takeda, Regeneron; support for attending meetings and\/or travel: Roche, Bristol, MSD, AstraZeneca, Janssen, Pfizer, Takeda, Regeneron. R.L. reports payment or honoraria from Takeda, AstraZeneca, Amgen, Bristol-Myers Squibb, Roche, Pierre-Fabre; support for attending meetings or travel from Roche, AstraZeneca, MSD, Takeda, Merck Serono. V.C. reports consulting fees from Roche, AstraZeneca, MSD, BMS, Takeda, Sanofi, Amgen, GSK, Boehringer Ingelheim, Janssen; payment or honoraria from Roche, AstraZeneca, MSD, BMS, Takeda, Sanofi, Amgen, Pfizer, Janssen, Beigene; support for attending meetings or travels: AstraZeneca, Roche, MSD, Takeda, Janssen. D.R-A. reports honoraria for lectures from MSD, Roche, BMS, Novartis, Takeda, Lilly, AstraZeneca. Support for attending meetings or travels from Roche, MSD, Novartis, Sanofi; advisory board participation with Merck Sharp Dohme, Regeneron, BMS, GSK, Lilly. J.B-B. reports consulting fees from Roche; payment or honoraria from BMS, Roche, AstraZeneca, Regeneron, MSD, Pfizer, Amgen; support for attending meetings or travels from MSD, Roche, Takeda. A.L-M. reports payment or honoraria from Pfizer, Lilly, Novartis; support for attending meetings or travels from MSD, AMGEM, Takeda; support for attending meetings or travels from MSD, Roche, Takeda. A.R. reports grants from EMQN; consulting fees from Johnson and Johnson, ThermoFisher; payment or honoraria from Illumina, Health in Code, ThermoFisher; support for attending meetings or travels from ThermoFisher, Bristol Myers Squibb; and Advisory Board participation with Takeda. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10124"}}